1. Co-Diagnostics to release Q3 2025 financial results on November 13. 2. A conference call will follow the results announcement at 4:30 p.m. ET. 3. Management will discuss pertinent financial details with analysts during the call. 4. CODX focuses on molecular diagnostics with patented testing technologies. 5. Their tests analyze DNA/RNA and other genetic markers.
Earnings calls can influence stock prices but depend on performance vs. expectations.
Earnings reports can affect share prices; however, no unusual market-shifting news is present.
Immediate implications expected around the earnings release date and call.
SALT LAKE CITY, Oct. 31, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its third quarter 2025 financial results on Thursday, November 13, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts. Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations.
The conference call and webcast will be available via:
Webcast: ir.co-dx.com on the Events & Webcasts page, or accessible directly here
Conference Call: 1-888-880-3330 (Toll Free) or 1-646-357-8766 (Toll)
If you are unable to participate during the live webcast, the call will be recorded and later made available on the Company's website.
About Co-Diagnostics, Inc.
Co-Diagnostics, Inc. (NASDAQ:CODX), a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed to detect and/or analyze nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.
View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-announces-third-quarter-2025-earnings-release-date-and-webcast-302600837.html
SOURCE Co-Diagnostics